Nivolumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Korean Patients with HER2-Negative, Untreated, Unresectable Advanced or Recurrent Gastric or Gastroesophageal Junction Cancer: Subgroup Analysis of a Randomized, Multicenter, Double-Blind Phase 3 Trial (ATTRACTION-4)
Cancer Research and Treatment · 2025
DOI: 10.4143/crt.2024.913 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Cancer Research and Treatment, 2025. Verfasst von Yoon-Koo Kang und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. ykkang@amc.seoul.kr. Hauptthemen laut MEDLINE: Stomach Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Esophagogastric Junction, Nivolumab. Die Arbeit wurde bisher 2-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Ono Pharmaceutical Co., Ltd, BristolMyers Squibb K.K.
Themen: Onkologische Pflege
Abstract (Originalsprache)
PURPOSE: We report the safety and efficacy of nivolumab+chemotherapy for first-line treatment of advanced or recurrent gastric or gastroesophageal junction cancer in the Korean subpopulation of the ATTRACTION-4 clinical trial. MATERIALS AND METHODS: ATTRACTION-4 (NCT02746796) was a double-blind, randomized, placebo-controlled clinical trial of patients aged ≥ 20 years with histologically confirmed unresectable advanced or recurrent gastric or gastroesophageal junction cancer. Patients received nivolumab or placebo, both combined with physician-choice chemotherapy (oxaliplatin plus oral S-1 [tegafur-gimeracil-oteracil] [SOX] or oral capecitabine [CAPOX]). RESULTS: Overall, 464 patients were initially screened in Korea and 291 were randomized to nivolumab+chemotherapy (total/SOX/CAPOX: 148/66/82 patients) or placebo+chemotherapy (total/SOX/CAPOX: 143/61/82 patients). Centrally assessed progression-free survival (median, 14.75 vs. 8.34 months; hazard ratio [HR], 0.53; 95% confidence interval [CI], 0.39 to 0.73; p < 0.001), overall survival (19.7 vs. 14.9 months; HR, 0.78; 95% CI, 0.60 to 1.02; p=0.065), overall response rate (54.7% vs. 47.6%), and duration of response (16.03 vs. 9.86 months) favored nivolumab+chemotherapy vs. placebo+chemotherapy. Grade ≥ 3 treatment-related adverse events (TRAEs) (56.1% vs. 44.1%), and any-grade endocrine (9.5% vs. 4.2%), hepatic (23.0% vs. 14.7%), hypersensitivity and infusion reactions (15.5% vs. 7.0%), renal (4.1% vs. 0.7%), and skin (44.6% vs. 23.1%) TRAEs tended to be more frequent in the nivolumab+chemotherapy group. CONCLUSION: These findings demonstrate the clinical benefit of nivolumab combined with chemotherapy (either SOX or CAPOX) for first-line treatment of gastric cancer/gastroesophageal junction cancer in Korean patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. ykkang@amc.seoul.kr.
- Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
- Department of Oncology, Seoul National University Hospital, Seoul, Korea.
- Department of Hematology and Oncology, Korea University Guro Hospital, Seoul, Korea.
- Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea.
- Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea.
Förderung
- Ono Pharmaceutical Co., Ltd
- BristolMyers Squibb K.K
Zitieren
APA
Kang, Y. K., Ryu, M. H., Oh, D. Y., Oh, S. C., Rha, S. Y., Lee, K. W., Chung, I. J., Oh, S. Y., Sym, S. J., Kang, W. K., Kim, J. G., Shim, B. Y., Kim, I. H., Kim, J. Y., Song, E. K., Lee, H. J., Kang, S. Y., Koo, D. H., & Oh, S. Y. (2025). Nivolumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Korean Patients with HER2-Negative, Untreated, Unresectable Advanced or Recurrent Gastric or Gastroesophageal Junction Cancer: Subgroup Analysis of a Randomized, Multicenter, Double-Blind Phase 3 Trial (ATTRACTION-4). Cancer Research and Treatment. https://doi.org/10.4143/crt.2024.913
Vancouver
Kang YK, Ryu MH, Oh DY, Oh SC, Rha SY, Lee KW, et al. Nivolumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Korean Patients with HER2-Negative, Untreated, Unresectable Advanced or Recurrent Gastric or Gastroesophageal Junction Cancer: Subgroup Analysis of a Randomized, Multicenter, Double-Blind Phase 3 Trial (ATTRACTION-4). Cancer Research and Treatment. 2025. doi:10.4143/crt.2024.913
BibTeX
@article{Kang2025,
author = {Kang, Yoon-Koo and Ryu, Min-Hee and Oh, Do-Youn and Oh, Sang Cheul and Rha, Sun Young and Lee, Keun-Wook and Chung, Ik Joo and Oh, Sung Yong and Sym, Sun Jin and Kang, Won Ki and Kim, Jong Gwang and Shim, Byoung Yong and Kim, In-Ho and Kim, Jin Young and Song, Eun-Kee and Lee, Hyo-Jin and Kang, Seok Yun and Koo, Dong-Hoe and Oh, So Yeon},
title = {Nivolumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Korean Patients with HER2-Negative, Untreated, Unresectable Advanced or Recurrent Gastric or Gastroesophageal Junction Cancer: Subgroup Analysis of a Randomized, Multicenter, Double-Blind Phase 3 Trial (ATTRACTION-4)},
journal = {Cancer Research and Treatment},
year = {2025},
doi = {10.4143/crt.2024.913}
}
EUVIMED